TREK-1 channel as a therapeutic target for dexmedetomidine-mediated neuroprotection in cerebral ischemia
Neurogenetics · 2024
DOI: 10.1007/s10048-024-00772-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogenetics, 2024. Verfasst von Yang Xu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Cancer Hospital Affiliated to Harbin Medical University, 150 Haping Road (Street), NanGang District, Harbin, 150081, He…. Hauptthemen laut MEDLINE: Dexmedetomidine, Potassium Channels, Tandem Pore Domain, Rats, Sprague-Dawley, Neuroprotective Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Our objective is to explore the protective effect of Dexmedetomidine on brain apoptosis and its mechanism through TREK-1 pathway. Forty male Sprague-Dawley rats were allocated into four groups: Sham, Cerebral Ischemia/Reperfusion Injury (CIRI), 50 µg/kg Dex, and 100 µg/kg Dex. A rat model of middle cerebral artery occlusion (MCAO) was employed to simulate cerebral embolism. Primary cortical neurons were exposed to Dex for 48 h, with some receiving additional treatment with 100 µM yohimbine hydrochloride (YOH) or TREK-1 small interfering RNA (siRNA). Neuronal damage was assessed using hematoxylin and eosin (HE) staining. Cell viability and apoptosis were measured by Cell Counting Kit-8 (CCK8) and flow cytometry, respectively. Protein and gene expression levels of Bcl-2, Bax, and TREK-1 were determined by Western blot and real-time polymerase chain reaction (PCR). Histopathological changes revealed that Dex treatment at both 50 µg/kg and 100 µg/kg significantly mitigated neuronal damage compared to the CIRI group. YOH treatment and Trek1 siRNA significantly reduced cell viability (p < 0.05). The mRNA expression and protein levels of TREK-1 and Bax were remarkably increased, while mRNA expression and protein levels of Bcl-2 was seriously decreased after CIRI modeling. In contrast, Dex treatment at both concentrations led to decreased TREK-1 and Bax expression and increased Bcl-2 expression in primary cortical neurons. Addition of 100 µM YOH and Trek1 siRNA reversed the effects of Dex on apoptosis-related genes (p < 0.05). Dex exerts neuroprotective effects through the TREK-1 pathway in vivo and in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Cancer Hospital Affiliated to Harbin Medical University, 150 Haping Road (Street), NanGang District, Harbin, 150081, Heilongjiang Province, PR China.
- Department of Anesthesiology, Cancer Hospital Affiliated to Harbin Medical University, 150 Haping Road (Street), NanGang District, Harbin, 150081, Heilongjiang Province, PR China. carline85@126.com.
Zitieren
APA
Xu, Y., Teng, X., Wei, M., & Liu, Y. (2024). TREK-1 channel as a therapeutic target for dexmedetomidine-mediated neuroprotection in cerebral ischemia. Neurogenetics. https://doi.org/10.1007/s10048-024-00772-w
Vancouver
Xu Y, Teng X, Wei M, Liu Y. TREK-1 channel as a therapeutic target for dexmedetomidine-mediated neuroprotection in cerebral ischemia. Neurogenetics. 2024. doi:10.1007/s10048-024-00772-w
BibTeX
@article{Xu2024,
author = {Xu, Yang and Teng, XiaoDan and Wei, Ming and Liu, Yang},
title = {TREK-1 channel as a therapeutic target for dexmedetomidine-mediated neuroprotection in cerebral ischemia},
journal = {Neurogenetics},
year = {2024},
doi = {10.1007/s10048-024-00772-w}
}
EUVIMED